Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal ...

PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker ...

Indian equity markets opened on a cautious note, a day after recording a sharp recovery that snapped a six-week losing streak ...

Pfizer has introduced its 20-valent pneumococcal conjugate vaccine, PCV20, in India to provide protection against 20 serotypes of pneumococcal disease. The single-shot vaccine is aimed at adults, ...

Pfizer introduces its next-gen 20-valent pneumococcal conjugate vaccine (PCV20) in India for adult immunization against 20 ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

This follows the recent announcement that the Health Ministry has approved the 20-valent pneumococcal conjugate vaccine ...

The 20-valent pneumococcal conjugate vaccine (PCV20, or Prevnar 20) produced a non-inferior immune response in adults to the 13-valent vaccine (PCV13, or Prevnar 13), with an adequate safety ...

V116 was non-inferior to PCV20 for the 10 serotypes common to both vaccines (3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, 33F), as assessed by serotype-specific OPA GMTs 30 days post-vaccination.

If a person receives PCV15, they may receive a dose of PPSV23 after 1 year. However, this is unnecessary with PCV20 and PCV21. » Learn more: Does Medicare cover pneumonia shots?

About the VAX-31 Phase 1/2 Study The VAX-31 Phase 1/2 clinical study is a randomized, observer-blind, active-controlled, dose-finding clinical study designed to evaluate the safety, tolerability ...